This application is filed with a Computer Readable Form of a Sequence Listing in accord with 37 C.F.R. § 1.821(c). The text file submitted by EFS, “026389-9276-WO01_sequence_listing_5 Aug. 2020_ST25.txt,” was created on Aug. 5, 2020, contains 6 sequences, has a file size of 92.3 Kbytes, and is hereby incorporated by reference in its entirety.
Described herein are photoswitchable compounds that can activate the TRPA1 channel in neuronal and non-neuronal cells. The TRPswitch molecules allow for optical control of both the activation and deactivation of the TRPA1 channel. Such compounds can be used as research tools or therapeutics.
Optogenetics has proven to be a transformative technology for various fields of basic research, particularly in neuroscience. It allows for a non-invasive, localized, and temporally selective optical modulation of selected cells within an animal. Optogenetic technologies hold great promise for clinical applications. For example, preclinical animal models have demonstrated potential utility in treating retinitis pigmentosa with AAV-delivered channelrhodopsin2 (ChR2) [1]. However, high expression of the light-gated ion channel ChR2, originating from green algae, has cytotoxic effects [2]. It remains unclear whether or not expression of ChR2 in humans will result in immune rejection or inflammation. Therefore, to advance the utility of optogenetics in clinical applications, development of optogenetic actuators that are vertebrate in origin or endogenous to humans, as well as those based on ion channels with high unitary conductance, will be advantageous. The use of vertebrate protein actuators should reduce the risk of immunological reactions due to long-term expression of exogenous proteins. High conductance actuators should also decrease the amount of channel expression needed for sufficient light-controlled activity. Some progress has been made toward these goals, including the development of an endogenous protein-targeting photoswitch that confers light-sensitivity on endogenous neuronal ion channels, proposed to have the potential to restore vision to the blind [3-5].
Discovery of new optogenetic actuators that possess novel and unique properties will undoubtedly enhance the ability to dissect biological systems such as the complex neuronal networks of the brain. For example, optogenetic experiments that require long activation periods would benefit greatly from “step function” optogenetic tools that allow stable, bi-directional on and off switching of channels. Step function opsins (SFOs) are engineered versions of ChR2 that provide longer off-time constants [6-8]. As such, they are useful in modifying the spontaneous firing rate of neurons, as well as in applications where behavioral analysis without continuous optic fiber tethering is desired [9-10]. However, as mentioned above, the non-vertebrate origin of these opsins present potential challenges in clinical applications. As a complementary approach, chemo-optogenetic tools that combine chemicals and optogenetics have been under rapid development. Using a chemical design approach, photochromic soluble ligands (PCLs) for various wild-type ion channels have been synthesized to allow for light-controlled channel activity [11-15]. These photoswitchable PCLs block and unblock their corresponding ion channel either in their E or Z configuration. Examples include PCLs for the TRPV1 channel [11], NMDA receptor [16-17], and kainate receptor [18-19].
Transient Receptor Potential Ankyrin 1 (TRPA1) is a member of the Transient Receptor Potential (TRP) channel family. It is a non-selective cation channel that plays an important role in inflammatory and neuropathic pain, itch, and respiratory diseases [20-22]. Photoactivable ligands for TRPA1, such as optovin, have the ability to act as chemo-optogenetic tools [23-24]. TRPA1 has a channel conductance of approximately 100 pS [25], 1,000 times greater than ChR2, making it ideal for applications where high conductance or low expression levels are desired. Importantly however, while photochemical stimulation of optovin-class chemo-optogenetic ligands activate TRPA1 rapidly (in low millisecond time scales), channel deactivation depends upon spontaneous (i.e. non-photochemical) reversal of ligand action, which occurs on the time scale of seconds. In other words, the approach is somewhat akin to photodecaging, where a “protected” ligand is activated (“deprotected”) following a light stimulus [26], but where deactivation requires spontaneous and often slow dissipation of the ligand. It would be a great advancement to develop a chemo-optogenetic system that preserves the high conductance of TRPA1 and the rapid activation of optovin-class ligands, but enables rapid, light-controlled channel deactivation: a photoreversible/photoswitchable system.
What is needed are photoswitchable compounds that can bind to and activate or deactivate the TRPA1 channel in neuronal and non-neuronal cells.
One embodiment described herein is a photoactive compound of Formula (I):
wherein each X is independently O or S and R is a substituted or unsubstituted heteroaryl moiety or a substituted phenyl moiety.
In another embodiment, the compound is one of Formulae (II), (Ill), or (IV):
wherein each X is independently O or S and R is a substituted or unsubstituted heteroaryl moiety or a substituted phenyl moiety. In one aspect, each X is independently O or S and R is a mono- or bi-cyclic aryl ring or a 5-10 membered mono or bi-cyclic heteroaryl ring optionally substituted with one or more of Q1-(R1)n; Q1 is a covalent bond, H, O, halogen, cyano, —NR3—, —CONR2—, —NR2CO—, oxo, nitro, —S(O)m—, —C1-6 haloalkyl, —C1-6 alkoxy, —C1-6 haloalkoxy, —C1-6 hydroxyalkyl, —C1-6 cyanoalkyl, —CO—, —SO2R3, —NR3R4, —NR3COR4, —NR2CONR3R4, —CONR3R4, —CO2R3, —NR3CO2R4, —SO2NR3R4, —CONR3, —C(O)R3, —NR3SO2R4, —NR2SO2NR3R4, —SO2NR3, optionally substituted —C1-6 alkylene, optionally substituted —C2-6 alkenylene, or optionally substituted —C1-6 alkyl; R1 is halogen, oxo, cyano, nitro, optionally substituted —C1-6 haloalkyl, optionally substituted —C1-6 alkoxy, optionally substituted —C1-6 haloalkoxy, optionally substituted —C1-6 alkyl, optionally substituted —C2-6 alkenyl, optionally substituted —C2-6 alkynyl, —C1-C6 hydroxyalkyl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, -Q2-NR5CONR6R7, -Q2-NR5R6, -Q2-NR5COR6, -Q2-COR5, -Q2-SO2R5, -Q2-CONR5, -Q2-CONR5R6, -Q2-CO2R5, -Q2-SO2NR5R6, -Q2-NR5SO2R6, or -Q2-NR5SO2NR6R7; Q2 is a covalent bond, —C1-6 alkyl, —C1-6 alkylene, or —C2-6 alkenylene; R2, R3, and R4 are each independently hydrogen, optionally substituted —C1-6 alkyl, or optionally substituted —C1-6 alkylene; R5, R6, and R7 are each independently H, optionally substituted —C1-6 alkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, or optionally substituted cycloalkyl; n is 0, 1, 2, 3, or 4; when n is 1, 2, 3, or 4, R1 is an optionally substituted 3-10 membered heterocyclyl, heteroaryl, aryl, or a mono- or bi-cycloalkyl ring; and wherein n is 0, Q is present and R1 is absent; m is 0, 1, or 2; and any of the compounds designated as “optionally substituted” may be substituted with halogen, —C1-6 alkyl, —C1-6 alkenyl, —C1-6 alkynyl, —C1-6 alkoxy, —C0-6 amine, —C0-6 amide, —C0-6—OH, —C0-6—COOH, —C0-6 CN, or C1-6 halogen. In one aspect, each X is S. In another aspect, each X is O.
In another embodiment, the compound is Formula (V):
wherein each X is S or O; R is
Y is independently O, S, or N; Q1 is a covalent bond, H, O, halogen, cyano, —NR3—, —CONR2—, —NR2CO—, oxo, nitro, —S(O)m—, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, —CO—, —SO2R3, —NR3R4, —NR3COR4, —NR2CONR3R4, —CONR3R4, —CO2R3, —NR3CO2R4, —SO2NR3R4, —CONR3, —C(O)R3, —NR3SO2R4, —NR2SO2NR3R4, —SO2NR3, optionally substituted —C1-6 alkylene, optionally substituted —C2-6 alkenylene, or optionally substituted —C1-6 alkyl; R1 is halogen, oxo, cyano, nitro, optionally substituted —C1-6 haloalkyl, optionally substituted —C1-6 alkoxy, optionally substituted —C1-6 haloalkoxy, optionally substituted —C1-6 alkyl, optionally substituted —C2-6 alkenyl, optionally substituted —C2-6 alkynyl, —C1-C6 hydroxyalkyl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, -Q2-NR5CONR6R7, -Q2-NR5R6, -Q2-NR5COR6, -Q2-COR5, -Q2-SO2R5, -Q2-CONR5, -Q2-CONR5R6, -Q2-CO2R5, -Q2-SO2NR5R6, -Q2-NR5SO2R6, or -Q2-NR5SO2NR6R7; Q2 is a covalent bond, —C1-6 alkyl, —C1-6 alkylene, or —C2-6 alkenylene; R2, R3, and R4 are each independently hydrogen, optionally substituted —C1-6 alkyl, or optionally substituted —C1-6 alkylene; R5, R6, and R7 are each independently H, optionally substituted —C1-6 alkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, or optionally substituted cycloalkyl; R3 is a covalent bond, hydrogen, halogen, oxygen, oxo, nitro, cyano, —NR3—, —CONR3—, —NR3CO—, —S(O)m—, C1-C6 haloalkyl, —C1-C6 alkoxy, —C1-C6 haloalkoxy, —C1-C6 hydroxyalkyl, —C1-C6 cyanoalkyl, —CO—, —SO2R4, —NR3R4, —NR3COR4, —NR2CONR3R4, —CONR3R4, —CO2R3, —NR3CO2R4, —SO2NR3R4, —CONR3, —C(O)R3, —NR3SO2R4, —NR2SO2NR3R4, —SO2NR3, optionally substituted C1-C6 alkylene, optionally substituted —C2-C6 alkenylene, or optionally substituted —C1-C6 alkyl; n is 0, 1, 2, 3, or 4; when n is 1, 2, 3, or 4, R1 is an optionally substituted 3-10 membered heterocyclyl, heteroaryl, aryl, or a mono- or bi-cycloalkyl ring; and wherein n is 0, Q is present and R1 is absent; m is 0, 1, or 2; and any of the compounds designated as “optionally substituted” may be substituted with halogen, —C0-6 alkyl, —C1-6 alkenyl, —C1-6 alkynyl, —C1-6 alkoxy, —C0-6 amine, —C0-6 amide, —C0-6—OH, —C0-6—COOH, —C0-6 CN, or C1-6 halogen.
In one aspect, each X is S or O and R is:
Y is independently O, S, or N; R9 is independently H, halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C0-6 amine, C0-6 amide, C0-6—OH, C0-6—COOH, C0-6 CN, C1-6 halogen, or —CF3; and n is 0, 1, 2, 3, or 4. In another aspect, each X is S or O and R is:
In another aspect, each X is S or O and R is:
In another embodiment, the compound is selected from:
In another aspect, each X is S or O, and R is a substituted or unsubstituted arylazopyrazole.
In another aspect, each X is S or O and R is
In another embodiment, the compound is:
Another embodiment described herein is a compound is a reversible photoswitch that acts on a TRPA1 channel.
Another embodiment described herein is a research tool comprising any of the compounds described herein.
Another embodiment described herein is a method for reversibly activating or deactivating a TRPA1 channel, the method comprising: contacting a TRPA1 channel with an E isomer of any of the compounds described herein; pulse illuminating the compound with violet light (˜350-405 nm) to induce an E→Z isomerization and activate the TRPA1 channel; and subsequently, pulse illuminating the compound with green light (˜500-600 nm) to induce a Z→E isomerization and deactivate the TRPA1 channel. In one aspect, the compound is:
In another aspect, the compound has a concentration of about 10-20 μM. In another aspect, the compound is administered to an organism, part thereof, or cell culture, and the organism, part thereof, or cell culture is pulse illuminated with violet light to activate and subsequently green light to deactivate the TRPA1 channel. In another aspect, the TRPA1 channel is a Trpa1b channel. In another aspect, the TRPA1 channel is a vertebrate Trpa1b channel. In another aspect, the TRPA1 channel is a zebrafish (Danio rerio) Trpa1b channel. In another aspect, activation of the TRPA1 channel leads to an increase in current and deactivation leads to a decrease in current.
Another embodiment described herein is a means for the activation or deactivation of a TRPA1 channel comprising contacting a TRPA1 channel with of any of the compounds described herein and pulse illuminating the compound with violet light to activate the TRPA1 channel or subsequently green light to deactivate the Trap1b channel.
Another embodiment described herein is the use of any of the compounds described herein for the reversible activation or deactivation of a TRPA1 channel.
Another embodiment described herein is a method for synthesizing of any of the compounds described herein, the method comprising: (a) reacting a pyrazole amine or a phenyl amine with a diazotizing mixture comprising sodium nitrite and one or more of HCl, H2SO4, HBF4, AcOH, or tosic acid and incubating for a period of time to produce a product; (b) adding benzene-1,3-diamine and sodium acetate in a methanol/water mixture to the product of (a); (c) performing an organic extraction and purifying the product of (b); (d) combining the purified product of (c) in pyridine with propylphosphonic anhydride (T3P) in ethyl acetate and heating for a period of time to produce a product; and (e) performing an organic extraction and purifying the product of (d); or (a1) reacting aniline with potassium peroxymonosulfate in a biphasic mixture of organic solvent and water under an oxygen free atmosphere and incubating for a period of time at room temperature to produce at product; (b1) performing an organic extraction of the product of (a1) to form an extracted product; (c1) reacting a nitrobenzene amine with either 2-furoyl chloride or 2-thiophenecarbonyl chloride and heating for a period of time to produce a product; (d1) purifying the product of (c1); (e1) combining the purified product of (d1) with a mixture of organic solvent, iron and an aqueous solution of ammonium chloride, and heating for a period of time to produce a product; (f1) purifying the product of (e1); (g1) reacting the purified product of (f1) with the extracted product of (b1) in an acid and an organic solvent and heating for a period of time to produce a product; and (h1) performing an organic extraction and purifying the product of (g1); or (a2) reacting an azobenzene amine with either 2-furoic acid or 2-thiophenecarboxylic acid in pyridine and propylphosphonic anhydride (T3P) in ethyl acetate and heating for a period of time to produce a product; and (b2) performing an organic extraction and purifying the product of (a2).
Another embodiment described herein is a reversible photoswitch compound synthesized by any of the methods described herein.
Another embodiment described herein is a kit comprising two or more of: Compound 9, a Trpa1b plasmid (pCMV-zTrpa1b-FLAG; SEQ ID NO:3); Tol2-ngn1-Trpa1b-2A-mCherry (partial vector sequence in SEQ ID NO:5); a zebrafish Trpa1b−/− embryo; a HEK293T cell expressing zebrafish Trpa1b; transfection reagents; buffers and reagents; a light source capable of illuminating in the violet and green wavelengths; packaging, containers, and instructions for use.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are those that are well known and commonly used in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present invention.
As used herein, the terms such as “include,” “including,” “contain,” “containing,” “having,” and the like mean “comprising.” The present disclosure also contemplates other embodiments “comprising,” “consisting of,” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
As used herein, the term “a,” “an,” “the” and similar terms used in the context of the disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. In addition, “a,” “an,” or “the” means “one or more” unless otherwise specified.
As used herein, the term “or” can be conjunctive or disjunctive.
As used herein, the term “substantially” means to a great or significant extent, but not completely.
As used herein, the term “about” or “approximately” as applied to one or more values of interest, refers to a value that is similar to a stated reference value, or within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, such as the limitations of the measurement system. In one aspect, the term “about” refers to any values, including both integers and fractional components that are within a variation of up to ±10% of the value modified by the term “about.” Alternatively, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, such as with respect to biological systems or processes, the term “about” can mean within an order of magnitude, in some embodiments within 5-fold, and in some embodiments within 2-fold, of a value.
All ranges disclosed herein include both end points as discrete values as well as all integers and fractions specified within the ranges. For example, a range of 0.1-2.0 includes 0.1, 0.2, 0.3, 0.4 . . . 2.0. If the end points are modified by the term “about,” the range specified is expanded by a variation of up to ±10% of any value within the range or within 3 or more standard deviations, including the end points. As used herein, the symbol “˜” means “about.” As used herein, the terms “active ingredient” or “active pharmaceutical ingredient” refer to a pharmaceutical agent, active ingredient, compound, or substance, compositions, or mixtures thereof, that provide a pharmacological, often beneficial, effect.
As used herein, the terms “control,” “reference level,” and “reference” are used herein interchangeably. The reference level may be a predetermined value or range, which is employed as a benchmark against which to assess the measured result. “Control group” as used herein refers to a group of control subjects.
As used herein, the term “dose” denotes any form of the active ingredient formulation or composition that contains an amount sufficient to produce a therapeutic effect with at least a single administration. “Formulation” and “composition” are used interchangeably herein.
As used herein, the term “prophylaxis” refers to preventing or reducing the progression of a disorder, either to a statistically significant degree or to a degree detectable to one skilled in the art.
As used herein, the terms “effective amount” or “therapeutically effective amount,” refers to a substantially non-toxic, but sufficient amount of an agent or a composition being administered that will prevent, treat, or ameliorate to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An effective amount may be based on factors individual to each patient, including, but not limited to, the patient's age, size, type or extent of disease, stage of the disease, route of administration, the type or extent of supplemental therapy used, ongoing disease process and type of treatment desired.
As used herein, “sample” or “test sample” as used herein can mean any sample in which the presence and/or level of a target is to be detected or determined or any sample comprising a compound or ion channel, or component thereof as described herein. Samples may include liquids, solutions, emulsions, or suspensions. Samples may include any biological fluid or tissue, such as blood, whole blood, fractions of blood such as plasma and serum, muscle, interstitial fluid, sweat, saliva, urine, tears, synovial fluid, bone marrow, cerebrospinal fluid, nasal secretions, sputum, amniotic fluid, bronchoalveolar lavage fluid, gastric lavage, emesis, fecal matter, lung tissue, peripheral blood mononuclear cells, total white blood cells, lymph node cells, spleen cells, tonsil cells, cancer cells, tumor cells, bile, digestive fluid, skin, or combinations thereof. The sample can be used directly as obtained from a subject or can be pre-treated, such as by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, and the like, to modify the character of the sample in some manner as discussed herein or otherwise as is known in the art.
As used herein, the term “subject” refers to an animal. Typically, the animal is a mammal. A subject also refers to, for example, primates (e.g., humans, male or female; infant, adolescent, or adult), pigs, cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, and the like. In one embodiment, the subject is a human. In another embodiment, the subject is a fish.
As used herein, a subject is “in need of” a treatment if such subject would benefit biologically, medically, or in quality of life from such treatment.
As used herein, the terms “inhibit,” “inhibition,” or “inhibiting” refer to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
As used herein, “treatment” or “treating” refers to means suppressing, repressing, reversing, alleviating, ameliorating, or inhibiting the progress of disease, or completely eliminating a disease. A treatment may be either performed in an acute or chronic way. The term also refers to reducing the severity of a disease or symptoms associated with such disease prior to affliction with the disease. Preventing the disease involves administering a composition or compound of the present invention to a subject prior to onset of the disease. Suppressing the disease involves administering a composition or compound of the present invention to a subject after induction of the disease but before its clinical appearance. Repressing or ameliorating the disease involves administering a composition or compound of the present invention to a subject after clinical appearance of the disease.
Definitions of specific functional groups and chemical terms are described in more detail herein. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th ed, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd ed, Cambridge University Press, Cambridge, 1987.
As used herein, the term “alkyl” refers to a radical of a straight chain or branched saturated hydrocarbon group having from 1 to 6 carbon atoms (“C1-6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1-6 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1-3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C1 alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-g alkyl”). Examples of C1-6 alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C4) (e.g., n-butyl, tert-butyl, sec-butyl, isobutyl), pentyl (C5) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tertiary amyl), and hexyl (C6) (e.g., n-hexyl).
As used herein, the term “alkylene” refers to a divalent radical of an alkyl group, e.g., —CH2—, —CH2CH2—, and —CH2CH2CH2—.
As used herein, the term “heteroalkyl” refers to an alkyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 10 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC1-10 alkyl”). In certain embodiments, the heteroalkyl group is an unsubstituted heteroC1-10 alkyl. In certain embodiments, the heteroalkyl group is a substituted heteroC1-10 alkyl.
As used herein, the term “heteroalkylene” refers to a divalent radical of a heteroalkyl group.
As used herein, the terms “alkoxy” or “alkoxyl” refers to an —O-alkyl radical. In some embodiments, the alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. In some embodiments, alkoxy groups are lower alkoxy, i.e., with between 1 and 6 carbon atoms. In some embodiments, alkoxy groups have between 1 and 4 carbon atoms.
As used herein, the term “aryl” refers to a stable, aromatic, mono- or bicyclic ring radical having the specified number of ring carbon atoms. Examples of aryl groups include, but are not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. The related term “aryl ring” likewise refers to a stable, aromatic, mono- or bicyclic ring having the specified number of ring carbon atoms.
As used herein, the term “heteroaryl” refers to a stable, aromatic, mono- or bicyclic ring radical having the specified number of ring atoms and comprising one or more heteroatoms individually selected from nitrogen, oxygen, or sulfur. The heteroaryl radical may be bonded via a carbon atom or heteroatom. Examples of heteroaryl groups include, but are not limited to, furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridazinyl, pyrimidyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, indazolyl, oxadiazolyl, benzothiazolyl, quinoxalinyl, and the like. The related term “heteroaryl ring” likewise refers to a stable, aromatic, mono- or bicyclic ring having the specified number of ring atoms and comprising one or more heteroatoms individually selected from nitrogen, oxygen, or sulfur. In certain embodiments, the heteroaryl group is an unsubstituted heteroaryl. In some embodiments, the heteroaryl group is a substituted heteroaryl. The substitution can be on any atom with the ability to accept a substitution.
As used herein, the term “carbocyclyl” refers to a stable, saturated, or unsaturated, non-aromatic, mono- or bicyclic (fused, bridged, or spiro) ring radical having the specified number of ring carbon atoms. Examples of carbocyclyl groups include, but are not limited to, the cycloalkyl groups identified above, cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like. In an embodiment, the specified number is C3-C12 carbons. The related term “carbocyclic ring” likewise refers to a stable, saturated, or unsaturated, non-aromatic, mono- or bicyclic (fused, bridged, or spiro) ring having the specified number of ring carbon atoms.
As used herein, the term “heterocyclyl” refers to a stable, saturated or unsaturated, non-aromatic, mono- or bicyclic (fused, bridged, or spiro) ring radical having the specified number of ring atoms and comprising one or more heteroatoms individually selected from nitrogen, oxygen and sulfur. The heterocyclyl radical may be bonded via a carbon atom or heteroatom. In an embodiment, the specified number is C3-C12 carbons. Examples of heterocyclyl groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuryl, tetrahydrothienyl, piperidyl, piperazinyl, tetrahydropyranyl, morpholinyl, perhydroazepinyl, tetrahydropyridinyl, tetrahydroazepinyl, octahydropyrrolopyrrolyl, and the like. The related term “heterocyclic ring” likewise refers to a stable, saturated or unsaturated, non-aromatic, mono- or bicyclic (fused, bridged, or spiro) ring having the specified number of ring atoms and comprising one or more heteroatoms individually selected from nitrogen, oxygen and sulfur.
As used herein the terms “halogen” or “halo” refers to fluorine (fluoro, —F), chlorine (chloro, —Cl), bromine (bromo, —Br), or iodine (iodo, —I).
As used herein the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Exemplary substitutents include H, halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C0-6 amine, C0-6 amide, C0-6—OH, C0-6—COOH, or C0-6 CN.
As used herein, the definition of each expression, e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
Described herein are TRPswitch compounds and methods for activating and deactivating ion channels with such compounds.
A customized, light-responsive chemical library coupled with a behavior-based screening assay with zebrafish larvae was used to discover “TRPswitch” azoarene photoswitchable ligands for the TRPA1 channel. TRPswitch molecules allow for optical control of both the activation and deactivation of the TRPA1 channel. This analysis suggests that the zebrafish Trpa1b channel is necessary and sufficient for TRPswitch light-induced activity. Channel activation and deactivation can be controlled by violet light and green light illumination, respectively. The TRPswitch/light induced TRPA1 channel activity is reversible and repeatable in vivo, and sustained channel activation is achieved after only a short pulse of light illumination. This appears to be the first described photoswitchable TRPA1 system. These data show that this TRPA1/TRPswitch system is a robust chemo-optogenetic tool that can be applied to both neuronal and non-neuronal cells. The TRPA1/TRPswitch system's step function properties, along with its high unitary conductance, make it a complementary alternative to existing chemo-optogenetic tools.
Using a zebrafish behavior-based screening strategy, “TRPswitch,” a photoswitchable non-electrophilic ligand scaffold for the TRPA1 channel was discovered. TRPA1 exhibits high unitary channel conductance, making it an ideal target for chemo-optogenetic tool development. Key molecular determinants for the activity of TRPswitch were elucidated and allowed for replacement of the TRPswitch azobenzene with a next generation azoheteroarene. The TRPswitch compounds enable reversible, repeatable, and nearly quantitative light-induced activation and deactivation of the vertebrate TRPA1 channel with violet and green light, respectively. The utility of TRPswitch compounds was demonstrated in larval zebrafish hearts exogenously expressing zebrafish Trpa1b, where heartbeat could be controlled using TRPswitch and light. Therefore, TRPA1/TRPswitch represents a novel step-function chemo-optogenetic system with a unique combination of high conductance, high efficiency, activity against an unmodified vertebrate channel, and capacity for bidirectional optical switching. This chemo-optogenetic system is particularly applicable in systems where a large depolarization current is needed, or sustained channel activation is desirable.
One embodiment described herein is a photoactive compound of Formula (I):
wherein each X is independently O or S and R is a substituted or unsubstituted heteroaryl moiety or a substituted phenyl moiety.
In another embodiment, the compound is one of Formulae (II), (Ill), or (IV):
wherein each X is independently O or S and R is a substituted or unsubstituted heteroaryl moiety or a substituted phenyl moiety. In one aspect, each X is independently O or S and R is a mono- or bi-cyclic aryl ring or a 5-10 membered mono or bi-cyclic heteroaryl ring optionally substituted with one or more of Q1-(R1)n; Q1 is a covalent bond, H, O, halogen, cyano, —NR3—, —CONR2—, —NR2CO—, oxo, nitro, —S(O)m—, —C1-6 haloalkyl, —C1-6 alkoxy, —C1-6 haloalkoxy, —C1-6 hydroxyalkyl, —C1-6 cyanoalkyl, —CO—, —SO2R3, —NR3R4, —NR3COR4, —NR2CONR3R4, —CONR3R4, —CO2R3, —NR3CO2R4, —SO2NR3R4, —CONR3, —C(O)R3, —NR3SO2R4, —NR2SO2NR3R4, —SO2NR3, optionally substituted —C1-6 alkylene, optionally substituted —C2-6 alkenylene, or optionally substituted —C1-6 alkyl; R1 is halogen, oxo, cyano, nitro, optionally substituted —C1-6 haloalkyl, optionally substituted —C1-6 alkoxy, optionally substituted —C1-6 haloalkoxy, optionally substituted —C1-6 alkyl, optionally substituted —C2-6 alkenyl, optionally substituted —C2-6 alkynyl, —C1-C6 hydroxyalkyl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, -Q2-NR5CONR6R7, -Q2-NR5R6, -Q2-NR5COR6, -Q2-COR5, -Q2-SO2R5, -Q2—CONR5, -Q2-CONR5R6, -Q2-CO2R5, -Q2-SO2NR5R6, -Q2-NR5SO2R6, or -Q2-NR5SO2NR6R7; Q2 is a covalent bond, —C1-6 alkyl, —C1-6 alkylene, or —C2-6 alkenylene; R2, R3, and R4 are each independently hydrogen, optionally substituted —C1-6 alkyl, or optionally substituted —C1-6 alkylene; R5, R6, and R7 are each independently H, optionally substituted —C1-6 alkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, or optionally substituted cycloalkyl; n is 0, 1, 2, 3, or 4; when n is 1, 2, 3, or 4, R1 is an optionally substituted 3-10 membered heterocyclyl, heteroaryl, aryl, or a mono- or bi-cycloalkyl ring; and wherein n is 0, Q is present and R1 is absent; m is 0, 1, or 2; and any of the compounds designated as “optionally substituted” may be substituted with halogen, —C1-6 alkyl, —C1-6 alkenyl, —C1-6 alkynyl, —C1-6 alkoxy, —C0-6 amine, —C0-6 amide, —C0-6—OH, —C0-6—COOH, —C0-6 CN, or C1-6 halogen. In one aspect, each X is S. In another aspect, each X is O.
In another embodiment, the compound is Formula (V):
wherein each X is S or O; R is
Y is independently O, S, or N; Q1 is a covalent bond, H, O, halogen, cyano, —NR3—, —CONR2—, —NR2CO—, oxo, nitro, —S(O)m—, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, —CO—, —SO2R3, —NR3R4, —NR3COR4, —NR2CONR3R4, —CONR3R4, —CO2R3, —NR3CO2R4, —SO2NR3R4, —CONR3, —C(O)R3, —NR3SO2R4, —NR2SO2NR3R4, —SO2NR3, optionally substituted —C1-6 alkylene, optionally substituted —C2-6 alkenylene, or optionally substituted —C1-6 alkyl; R1 is halogen, oxo, cyano, nitro, optionally substituted —C1-6 haloalkyl, optionally substituted —C1-6 alkoxy, optionally substituted —C1-6 haloalkoxy, optionally substituted —C1-6 alkyl, optionally substituted —C2-6 alkenyl, optionally substituted —C2-6 alkynyl, —C1-C6 hydroxyalkyl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, -Q2-NR5CONR6R7, -Q2-NR5R6, -Q2-NR5COR6, -Q2-COR5, -Q2-SO2R5, -Q2-CONR5, -Q2-CONR5R6, -Q2-CO2R5, -Q2-SO2NR5R6, -Q2-NR5SO2R6, or -Q2-NR5SO2NR6R7; Q2 is a covalent bond, —C1-6 alkyl, —C1-6 alkylene, or —C2-6 alkenylene; R2, R3, and R4 are each independently hydrogen, optionally substituted —C1-6 alkyl, or optionally substituted —C1-6 alkylene; R5, R6, and R7 are each independently H, optionally substituted —C1-6 alkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, or optionally substituted cycloalkyl; R3 is a covalent bond, hydrogen, halogen, oxygen, oxo, nitro, cyano, —NR3—, —CONR3—, —NR3CO—, —S(O)m—, C1-C6 haloalkyl, —C1-C6 alkoxy, —C1-C6 haloalkoxy, —C1-C6 hydroxyalkyl, —C1-C6 cyanoalkyl, —CO—, —SO2R4, —NR3R4, —NR3COR4, —NR2CONR3R4, —CONR3R4, —CO2R3, —NR3CO2R4, —SO2NR3R4, —CONR3, —C(O)R3, —NR3SO2R4, —NR2SO2NR3R4, —SO2NR3, optionally substituted C1-C6 alkylene, optionally substituted —C2-C6 alkenylene, or optionally substituted —C1-C6 alkyl; n is 0, 1, 2, 3, or 4; when n is 1, 2, 3, or 4, R1 is an optionally substituted 3-10 membered heterocyclyl, heteroaryl, aryl, or a mono- or bi-cycloalkyl ring; and wherein n is 0, Q is present and R1 is absent; m is 0, 1, or 2; and any of the compounds designated as “optionally substituted” may be substituted with halogen, —C0-6 alkyl, —C1-6 alkenyl, —C1-6 alkynyl, —C1-6 alkoxy, —C0-6 amine, —C0-6 amide, —C0-6—OH, —C0-6—COOH, —C0-6 CN, or C1-6 halogen.
In one aspect, each X is S or O and R is:
Y is independently O, S, or N; R9 is independently H, halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C0-6 amine, C0-6 amide, C0-6—OH, C0-6—COOH, C0-6 CN, C1-6 halogen, or —CF3; and n is 0, 1, 2, 3, or 4. In another aspect, each X is S or O and R is:
In another aspect, each X is S or O and R is:
In another embodiment, the compound is selected from:
In another aspect, each X is S or O, and R is a substituted or unsubstituted arylazopyrazole.
In another aspect, each X is S or O and R is
In another embodiment, the compound is:
The disclosed compounds may exist as a pharmaceutically acceptable salt. The term “pharmaceutically acceptable salt” refers to salts or zwitterions of the compounds which are water or oil-soluble or dispersible, suitable for treatment of disorders without undue toxicity, irritation, and allergic response, commensurate with a reasonable benefit/risk ratio and effective for their intended use. The salts may be prepared during the final isolation and purification of the compound or separately by reacting an amino group of the compound with a suitable acid. For example, a compound may be dissolved in a suitable solvent, such as but not limited to methanol and water and treated with at least one equivalent of an acid, like hydrochloric acid. The resulting salt may precipitate out and be isolated by filtration and dried under reduced pressure. Alternatively, the solvent and excess acid may be removed under reduced pressure to provide a salt. Representative salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, isethionate, fumarate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, oxalate, maleate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, glutamate, para-toluenesulfonate, undecanoate, hydrochloric, hydrobromic, sulfuric, phosphoric and the like. The amino groups of the compound may also be quaternized with alkyl chlorides, bromides, and iodides such as methyl, ethyl, propyl, isopropyl, butyl, lauryl, myristyl, stearyl and the like.
Basic addition salts may be prepared during the final isolation and purification of the disclosed compound by reaction of a carboxyl group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation such as lithium, sodium, potassium, calcium, magnesium, or aluminum, or an organic primary, secondary, or tertiary amine. Quaternary amine salts can be prepared, such as those derived from methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, N,N′-dibenzylethylenediamine, ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, and the like.
Another embodiment described herein is a compound described herein that is a reversible photoswitch that acts on a TRPA1 channel.
Another embodiment described herein is a research tool comprising any of the compounds described herein.
Another embodiment described herein is a method for reversibly activating or deactivating a TRPA1 channel, the method comprising: contacting a TRPA1 channel with an E isomer of any of the compounds described herein; pulse illuminating the compound with violet light (˜350-405 nm) to induce an E→Z isomerization and activate the TRPA1 channel; and subsequently, pulse illuminating the compound with green light (˜500-600 nm) to induce a Z→E isomerization and deactivate the TRPA1 channel. In one aspect, the compound is:
In another aspect, the compound has a concentration of about 10-20 μM. In another aspect, the compound is administered to an organism, part thereof, or cell culture, and the organism, part thereof, or cell culture is pulse illuminated with violet light to activate and subsequently green light to deactivate the TRPA1 channel. In another aspect, the TRPA1 channel is a Trpa1b channel. In another aspect, the TRPA1 channel is a vertebrate Trpa1b channel. In another aspect, the TRPA1 channel is a zebrafish (Danio rerio) Trpa1b channel. In another aspect, activation of the TRPA1 channel leads to an increase in current and deactivation leads to a decrease in current.
Another embodiment described herein is a means for the activation or deactivation of a TRPA1 channel comprising contacting a TRPA1 channel with of any of the compounds described herein and pulse illuminating the compound with violet light to activate the TRPA1 channel or subsequently green light to deactivate the Trap1b channel.
Another embodiment described herein is the use of any of the compounds described herein for the reversible activation or deactivation of a TRPA1 channel.
Another embodiment described herein is a method for synthesizing of any of the compounds described herein, the method comprising: (a) reacting a pyrazole amine or a phenyl amine with a diazotizing mixture comprising sodium nitrite and one or more of HCl, H2SO4, HBF4, AcOH, or tosic acid and incubating for a period of time to produce a product; (b) adding benzene-1,3-diamine and sodium acetate in a methanol/water mixture to the product of (a); (c) performing an organic extraction and purifying the product of (b); (d) combining the purified product of (c) in pyridine with propylphosphonic anhydride (T3P) in ethyl acetate and heating for a period of time to produce a product; and (e) performing an organic extraction and purifying the product of (d); or (a1) reacting aniline with potassium peroxymonosulfate in a biphasic mixture of organic solvent and water under an oxygen free atmosphere and incubating for a period of time at room temperature to produce at product; (b1) performing an organic extraction of the product of (a1) to form an extracted product; (c1) reacting a nitrobenzene amine with either 2-furoyl chloride or 2-thiophenecarbonyl chloride and heating for a period of time to produce a product; (d1) purifying the product of (c1); (e1) combining the purified product of (d1) with a mixture of organic solvent, iron and an aqueous solution of ammonium chloride, and heating for a period of time to produce a product; (f1) purifying the product of (e1); (g1) reacting the purified product of (f1) with the extracted product of (b1) in an acid and an organic solvent and heating for a period of time to produce a product; and (h1) performing an organic extraction and purifying the product of (g1); or (a2) reacting an azobenzene amine with either 2-furoic acid or 2-thiophenecarboxylic acid in pyridine and propylphosphonic anhydride (T3P) in ethyl acetate and heating for a period of time to produce a product; and (b2) performing an organic extraction and purifying the product of (a2).
Another embodiment described herein is a reversible photoswitch compound synthesized by any of the methods described herein.
Another embodiment described herein is a kit comprising two or more of: Compound 9, a Trpa1b plasmid (pCMV-zTrpa1b-FLAG; SEQ ID NO:3); Tol2-ngn1-Trpa1b-2A-mCherry (partial vector sequence in SEQ ID NO:5); a zebrafish Trpa1b−/− embryo; a HEK293T cell expressing zebrafish Trpa1b; transfection reagents; buffers and reagents; a light source capable of illuminating in the violet and green wavelengths; packaging, containers, and instructions for use.
These studies have identified TRPswitch A and B, two photoswitchable small molecules that enable optical control of currents in the Trpa1b expressing cells in vivo. These data suggest that the TRPswitches specifically target Trpa1b channel and enable repeatable optical control of both neuronal and non-neuronal cells. This is the first example of TRPA1 channel activation by a photoswitchable compound. Importantly, the TRPswitches allow for sustained channel activation after only a brief pulse of violet light illumination, but the channel can also be rapidly deactivated with green light illumination. As only short pulses of light are required to control the activity of the TRPA1 channel, cells subjected to the TRPA1/TRPswitch chemo-optogenetic system are less prone to phototoxicity. This requirement of a short photoactivation period for target activation is a unique and advantageous feature among current PCLs for unmodified ion channels [11-15] and receptors [44].
The TRPA1 channel's high conductance combined with the step function property of the TRPA1/TRPswitch chemo-optogenetic system offers certain new opportunities for basic research. As TRPswitch activity is specific to zebrafish Trpa1b, TRPswitch can be used in heterologous applications by expressing zTrpa1b in animals or cells with endogenous mammalian TRPA1 expression, without interference from the endogenous channel. This new tool will be particularly beneficial in applications where a large depolarization current is needed, such as in large primary motor neurons, or when sustained channel activation is desirable. In addition, tools for manipulating TRPA1 activity are relevant for medical research since TRPA1 is involved in inflammatory and neuropathic pain, itch, and respiratory diseases [20-21, 45]. TRPswitch may prove useful as a research tool to help dissect the mechanism of TRPA1-related disease, as well as to identify disease-modifying agents.
The TRPA1/TRPswitch chemo-optogenetic system offers several advantages over existing tools and was shown here to be robust and easy to use in cultured mammalian cells and in zebrafish. TRPswitch is a freely diffusible small molecule and exposing zebrafish larvae by incubating them in a solution containing TRPswitch is sufficient for robust activity. The uptake and distribution in rodents and larger mammals may be similar to that of zebrafish larvae. When the zebrafish larvae were incubated with TRPswitch for several hours, no obvious adverse physiological phenotypes were observed. The TRPswitches show minimal activity on TRPA1 before photoactivation, highlighting the specificity of the light-induced effect of TRPswitch. On the other hand, as the TRPswitches display a wide range of spectral activity, it may be difficult to combine a TRPswitch with other optogenetic tools or fluorescence-based biosensors due to potential spectral overlap. The use of violet light for TRPswitch activation may also limit the tissue depth of its activation; however, multi-photon [46] or longer near infrared (NIR) light excitation [47] may be used.
This analysis suggests that both TRPswitch-A and TRPswitch-B have thermal half-lives in the scale of hours in DMSO. However, the half-life of the biological response to these compounds was measured to be in the timescale of minutes during in vivo cardiac experiments (
Most of the known TRPA1 ligands are electrophiles that activate TRPA1 via the covalent modification of cysteine residues present in the channel's cytoplasmic ankyrin repeat domain [48]. This includes the previously identified TRPA1 photoactivatable ligand, optovin [23-24]. Although both optovin and TRPswitch target TRPA1 and are activated by violet light, they are unique in their mechanism of action, reversibility, and kinetics. Unlike optovin and its derivatives, which act though light-induced covalent modification, TRPswitch's photoreversible TRPA1 activity depends on differential activity of its E and Z isomers. How isomerization triggers opening and closing of the TRPA1 channel remains unknown. Mechanistically, the fifth transmembrane (TM5) domain of TRPA1 has been shown to determine channel sensitivity to non-electrophilic agonists such as menthol and anethole [49-50]. Considering that menthol and anethole are structurally distinct molecules, TRPA1's TM5 may act as a general binding site for non-electrophilic agonists and may therefore be a candidate site for the binding of TRPswitch. Alternatively, a peptidergic scorpion toxin (WaTx) was recently discovered that activates TRPA1 by binding to the same allosteric nexus that is covalently modified by electrophilic irritants [51]. It is possible that the TRPswitches bind to this allosteric nexus on TRPA1 channel as well.
The development of PCLs for endogenous targets offers theoretical advantages in clinical applications since the introduction of exogenous gene products is not needed. The common approach for PCL discovery is to modify a known biologically active molecule with photoswitchable functionality, such as “azologization” [52]. Although this approach has had some success [11-15], it is limited by the need for already identified active molecules for specific targets, which have a defined mechanism of activation and that contain a chemical structure amenable to incorporation of a photoswitch. The screening strategy described here offers an alternative, phenotypic approach for the discovery of photoswitchable ligands of novel endogenous targets [53]. Since screening is performed using intact animals, hit compounds identified are, by definition, biologically active and likely to have minimal general toxicity. It should also be noted that despite having excellent and tunable switching properties, heteroaryl azo motifs are still significantly under-explored compared to their azobenzene counterparts in photoaddressible applications including as PCLs [54]. The discovery that the azopyrazole-containing TRPswitch-B exhibits a longer half-life and more efficient photoswitching than the azobenzene-containing TRPswitch-A is a good indication that heteroaryl azo photoswitches are good alternatives for photoswitch optimization. Indeed, this is the first application of the high performance arylazopyrazoles [32, 40] for in vivo photopharmacology, showcasing the potential of this scaffold for future studies.
It will be apparent to one of ordinary skill in the relevant art that suitable modifications and adaptations to the compositions, formulations, methods, processes, and applications described herein can be made without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any of the specified embodiments. All the various embodiments, aspects, and options disclosed herein can be combined in any variations or iterations. The scope of the compositions, formulations, methods, and processes described herein include all actual or potential combinations of embodiments, aspects, options, examples, and preferences herein described. The compositions, formulations, or methods described herein may omit any component or step, substitute any component or step disclosed herein, or include any component or step disclosed elsewhere herein. The ratios of the mass of any component of any of the compositions or formulations disclosed herein to the mass of any other component in the formulation or to the total mass of the other components in the formulation are hereby disclosed as if they were expressly disclosed. Should the meaning of any terms in any of the patents or publications incorporated by reference conflict with the meaning of the terms used in this disclosure, the meanings of the terms or phrases in this disclosure are controlling. Furthermore, the specification discloses and describes merely exemplary embodiments. All patents and publications cited herein are incorporated by reference herein for the specific teachings thereof.
All reagents and solvents were purchased from commercial sources and used as supplied unless otherwise indicated. All reactions were carried out under an inert atmosphere and using anhydrous solvents. All reactions were monitored by thin-layer chromatography (TLC) using Merck silica gel 60 F254 plates (0.25 mm). TLC plates were visualised using UV light (254 nm) and/or by using the appropriate TLC stain. Silica column chromatography was performed using Merck Silica Gel 60 (230-400 mesh) treated with a solvent system specified in the individual procedures. Solvents were removed by rotary evaporator at 40° C. or below and the compounds further dried using high vacuum pumps. Infrared spectra were recorded neat on an Agilent Cary 630 FTIR. Reported absorptions are in wavenumbers (cm−1). 1H and 13C NMR were recorded on a Bruker Avance 400 spectrometer at 400 MHz and 100 MHz, respectively. Chemical shifts (6) are quoted in ppm (parts per million) downfield from tetramethylsilane, referenced to residual solvent signals: 1H δ=7.26 (CHCl3), 2.50 (DMSO-d5), 13C δ=77.16 (CDCl3), 39.52 (DMSO-d6). The following abbreviations are used to designate multiplicity within 1H NMR analysis; s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br.=broad signal. High-resolution mass spectra (ESI, APCI) were recorded by the Imperial College London Department of Chemistry Mass Spectroscopy Service using a Micromass Autospec Premier and Micromass LCT Premier spectrometer. LCMS analysis of compounds were conducted using a reverse phase LCMS Waters 2767 system equipped with a photodiode array and an ESI mass spectrometer using an XBridge C18 (5 μm, 100 mm×4.6 mm) column, equipped with an XBridge C18 guard column (5 μm, 4.6 mm×20 mm). An eluent of MeCN and H2O was used: 0-10 min 50-98% MeCN, 10-12 min 98% MeCN, 12-13 min 98 to 50% MeCN, 13-17 min 50% MeCN (Method A). Flow rate: 1.2 mL/min. Alternatively, a PerkinElmer Series 200 HPLC equipped with a Supelco LC-SI (5 μm, 300 mm×4.0 mm) column was used. An eluent of isopropanol and hexane was used: 0-15 min 90% IPA (Method B) or 0-30 min 90% IPA (Method C). Flow rate: 0.3 mL/min.
A suspension of the relevant amine/aniline (1.0 eq.) in 1 M HCl (4 mL/mmol) was prepared and, if necessary, MeOH was added to aid solubility. This solution was cooled to −5° C. using an ice-brine bath before NaNO2 (1.1 eq.) in H2O (1 mL/mmol) was added dropwise. The resulting solution was stirred for 35 min before a solution of benzene-1,3-diamine (1.0 eq.) and NaOAc (3 eq.) in MeOH/H2O was added gradually. The pH of the resulting suspension was checked and, if necessary, made to pH 9-10 using 2 M NaOH. EtOAc was added, separated off and an extraction carried out with EtOAc three more times. The combined organic phases were washed with brine, dried over anhydrous Mg2SO4, concentrated in vacuo, and subjected to purification by silica column chromatography using solvent systems as described in the individual protocols.
To a solution of the relevant aniline (1.0 eq.) and acid (2.0 eq.) in pyridine (5 mL/mmol) propylphosphonic anhydride (T3P) 50 wt. % in EtOAc (3.0 eq.) was added. The reaction was heated to 90° C. for 4 hr. EtOAc/H2O were added, and the two layers separated. The aqueous layer was extracted with EtOAc three more times. The combined organic phases were washed with 1 M HCl, saturated NaHCO3, brine, dried over anhydrous Mg2SO4, concentrated in vacuo, and subjected to purification by silica column chromatography using solvent systems as described in the individual protocols.
The synthesis of nitrosobenzene derivatives followed a literature procedure described by Priewisch and RQck-Braun, J. Org. Chem. 70(6): 2350-2352 (2005) [58].
To a solution of N,N′-(4-amino-1,3-phenylene)bis(furan-2-carboxamide) (1.0 eq.) in AcOH:CHCl3 (1:1) was added the relevant nitrosobenzene derivative (1.2 eq.). The reaction was heated to 60° C. and monitored by thin layer chromatography. Upon completion of the reaction, the mixture was cooled room temperature, EtOAc/H2O was added, and the two layers separated. The aqueous layer was extracted with EtOAc three additional times. The combined organic phases were washed with 1 M HCl, saturated NaHCO3, brine, dried over anhydrous Mg2SO4, concentrated in vacuo, and subjected to purification by silica column chromatography.
4-nitrobenzene-1,3-diamine (1.5 g, 9.80 mmol) was added to neat 2-furoyl chloride (50 mL). The reaction was then heated to 100° C. and DMF (10 mL) was added in one portion. The reaction was held at this temperature for 18 h. Subsequently, the reaction was cooled and poured into ice-water to precipitate the crude product. This was further purified by recrystallisation from CHCl3/MeOH. The title compound was obtained as a yellow solid (2.3 g, 6.68 mmol, 68% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 10.79 (s, 1H), 8.77 (d, J=2.4 Hz, 1H), 8.17 (d, J=9.3 Hz, 1H), 8.00 (dd, J=13.0, 2.1 Hz, 2H), 7.77 (dd, J=9.3, 2.4 Hz, 1H), 7.46 (d, J=3.8 Hz, 1H), 7.37 (d, J=3.9 Hz, 1H), 6.75 (ddd, J=9.0, 3.4, 1.7 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 156.7, 155.9, 146.9, 146.8, 146.7, 144.8, 134.8, 133.7, 126.9, 116.4, 116.3, 115.7, 113.6, 112.9, 112.5; HRMS m/z calculated for C16H12N3O6 [M+H]+ 342.0726; found 342.0726.
To a suspension of N,N′-(4-nitro-1,3-phenylene)bis(furan-2-carboxamide) (1.0 g, 2.93 mmol) in DCM:MeOH (2:1, 50 mL) was added saturated aqueous NH4Cl (1.5 mL) and Fe (8.5 g, 151 mmol). The reaction was refluxed for 18 h. Subsequently, the mixture was filtered through Celite, concentrated in vacuo and the crude material purified by passing it through a silica plug. The title compound was obtained as a brown solid (800 mg, 2.57 mmol, 88% yield). 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 8.31 (s, 1H), 7.65 (d, J=2.4 Hz, 1H), 7.42 (ddd, J=7.5, 1.8, 0.9 Hz, 2H), 7.27 (dd, J=8.8, 2.6 Hz, 1H), 7.19-7.09 (m, 2H), 6.68 (d, J=8.6 Hz, 1H), 6.46 (dt, J=3.6, 1.8 Hz, 2H), 3.47 (s br., 2H); 13C NMR (101 MHz, CDCl3) δ 156.8, 156.4, 147.9, 147.5, 144.7, 144.3, 137.6, 129.4, 124.1, 119.9, 118.5, 117.8, 115.4, 114.8, 112.4; HRMS m/z calculated for C16H14N3O4 [M+H]+ 312.0984; found 312.0979.
Synthesized from aniline according to General Procedure C. The crude product was used immediately in the next step without further purification due to its perceived instability.
Synthesized from 4-aminobenzonitrile according to General Procedure C. The crude product was used immediately in the next step without further purification due to its perceived instability.
Synthesized from 4-nitroaniline according to General Procedure C. The crude product was used immediately in the next step without further purification due to its perceived instability.
General procedure B was followed using (E)-4-(phenyldiazenyl)benzene-1,3-diamine hydrochloride (200 mg, 0.80 mmol), furan-2-carboxylic acid (180 mg, 1.61 mmol) and T3P (1.4 mL, 2.4 mmol). Purified using a gradient of 0-20% EtOAc/CH2Cl2. The title compound was obtained as an orange solid (186 mg, 0.46 mmol, 58% yield). LCMS Method A (9.19 min); 1H NMR (400 MHz, DMSO-d6) δ 11.49 (s, 1H), 10.66 (s, 1H), 9.00 (d, J=2.3 Hz, 1H), 8.11 (dd, J=1.8, 0.8 Hz, 1H), 8.02-7.82 (m, 5H), 7.69-7.52 (m, 3H), 7.48 (dd, J=3.6, 0.8 Hz, 1H), 7.39 (dd, J=3.5, 0.8 Hz, 1H), 6.77 (ddd, J=19.3, 3.5, 1.7 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 156.5, 155.8, 151.9, 147.4, 147.1, 146.4, 146.3, 142.9, 135.8, 135.3, 131.3, 129.7, 123.6, 122.3, 115.7, 115.7, 115.5, 112.8, 112.3, 111.5; HRMS m/z calculated for C22H16N4O4Na [M+H]+ 423.1060; found 423.1069; IR: 3332, 3131, 1672, 1657.
To a stirred solution of 1,2-diaminobenzene (820 mg, 7.59 mmol) and AcOH (1.7 mL, 30 mmol) in CHCl3 (20 mL) was added nitrosobenzene (812 mg, 7.59 mmol). The mixture was refluxed for 24 h. The reaction was then concentrated in vacuo, with any AcOH subjected to azeotropic removal with toluene. The crude was purified by silica column chromatography on a gradient of 5-7% EtOAc/pentane. The title compound was obtained as a maroon solid (608 mg, 3.08 mmol, 41% yield). LCMS Method A (6.79 min); 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J=7.7 Hz, 2H), 7.61-7.42 (m, 2H), 7.32-7.20 (m, 1H), 6.87 (t, J=7.6 Hz, 1H), 6.80 (d, J=8.2 Hz, 1H), 5.93 (br. s, 2H); 13C NMR (101 MHz, CDCl3) δ 153.1, 143.1, 137.2, 132.4, 130.1, 129.2, 127.8, 122.3, 117.5, 117.1; HRMS m/z calculated for C12H12N3[M+H]+ 198.1031; found 198.1025; IR: 3463, 3364, 3058, 1603, 1570.
General procedure B was followed using (E)-2-(phenyldiazenyl)aniline (100 mg, 0.51 mmol), furan-2-carboxylic acid (114 mg, 1.02 mmol) and T3P (0.9 mL, 1.5 mmol). Purified using a gradient of 0-10% EtOAc/CH2Cl2. The title compound was obtained as a yellow solid (82 mg, 0.28 mmol, 55% yield). LCMS Method A (10.29 min); 1H NMR (400 MHz, DMSO-d6) δ 11.15 (s, 1H), 8.46 (dd, J=8.3, 1.3 Hz, 1H), 8.10-8.06 (m, 1H), 8.00-7.94 (m, 2H), 7.87 (dd, J=8.1, 1.5 Hz, 1H), 7.70-7.56 (m, 4H), 7.40-7.31 (m, 2H), 6.77 (dd, J=3.5, 1.8 Hz, 1H); 156.0, 151.9, 147.3, 146.4, 140.1, 135.0, 132.8, 131.9, 129.7, 124.5, 122.6, 121.6, 121.3, 115.7, 112.8; HRMS m/z calculated for C17H14N3O2 [M+H]+ 292.1086; found 292.1093; IR: 3147, 3101, 3060, 1660, 1577.
General procedure B was followed using (E)-4-(phenyldiazenyl)benzene-1,3-diamine hydrochloride (500 mg, 2.01 mmol), thiophene-2-carboxylic acid (515 mg, 4.02 mmol) and T3P (3.6 mL, 6.0 mmol). Purified using a gradient of 0-5% EtOAc/CH2Cl2. The title compound was obtained as an orange solid (592 mg, 1.37 mmol, 68% yield). LCMS Method A (10.72 min); 1H NMR (400 MHz, DMSO-d6) δ 10.94 (s, 1H), 10.66 (s, 1H), 8.73 (d, J=2.0 Hz, 1H), 8.14 (dd, J=3.7, 1.2 Hz, 1H), 8.03 (dd, J=3.8, 1.2 Hz, 1H), 7.97-7.89 (m, 4H), 7.90-7.82 (m, 2H), 7.65-7.50 (m, 3H), 7.28 (ddd, J=14.8, 5.0, 3.8 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 160.3, 159.8, 152.3, 142.8, 139.6, 139.4, 137.5, 136.4, 132.7, 132.5, 131.2, 129.9, 129.5, 128.5, 128.3, 122.5, 120.3, 116.3, 113.6; HRMS m/z calculated for C22H17N4O2S2[M+H]+ 433.0793; found 433.0806; IR: 3387, 3100, 1664, 1641, 1592.
General procedure A was followed using 4-aminobenzonitrile (500 mg, 4.23 mmol), NaNO2 (321 mg, 4.66 mmol), benzene-1,3-diamine (457 mg, 4.23 mmol) and NaOAc (1.04 g, 12.7 mmol). Purified using a gradient of 20-80% EtOAc/CH2Cl2. The title compound was obtained as a black solid (391 mg, 1.65 mmol, 39% yield). LCMS Method A (0.98 min); 1H NMR (400 MHz, DMSO-d6) δ 7.87-7.75 (m, 4H), 7.38 (d, J=8.9 Hz, 1H), 6.30 (br. s, 2H), 6.05 (dd, J=8.9, 2.3 Hz, 1H), 5.85 (d, J=2.1 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 156.1, 154.7, 133.2, 130.1, 121.3, 119.4, 108.0, 107.1, 95.6; HRMS m/z calculated for C13H12N5[M+H]+ 238.1088; found 238.1093; IR: 3454, 3425, 3357, 3233, 2214, 1577.
General procedure B was followed using (E)-4-((2,4-diaminophenyl)diazenyl)benzonitrile (318 mg, 1.34 mmol), furan-2-carboxylic acid (301 mg, 2.68 mmol) and T3P (2.4 mL, 4.0 mmol). Purified using a gradient of 0-10% EtOAc/CH2Cl2. The title compound was obtained as a red solid (467 mg, 1.10 mmol, 82% yield). LCMS Method B (10.38 min); 1H NMR (400 MHz, DMSO-d6) δ 11.40 (s, 1H), 10.68 (s, 1H), 8.98 (d, J=2.2 Hz, 1H), 8.10-7.95 (m, 6H), 7.92-7.79 (m, 2H), 7.47 (dd, J=3.6, 0.8 Hz, 1H), 7.37 (dd, J=3.5, 0.8 Hz, 1H), 6.75 (ddd, J=15.2, 3.5, 1.7 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 156.5, 155.9, 154.1, 147.3, 147.1, 146.4, 144.1, 136.1, 136.0, 134.0, 123.8, 122.9, 118.6, 115.8, 115.8, 112.9, 112.8, 112.4, 111.4; HRMS m/z calculated for C23H16N5O4[M+H]+ 426.1202; found 426.1206; IR: 3133, 3112, 2223, 1653, 1579.
General procedure B was followed using (E)-4-((2,4-diaminophenyl)diazenyl)benzonitrile (102 mg, 0.43 mmol), thiophene-2-carboxylic acid (110 mg, 0.86 mmol) and T3P (0.8 mL, 1.3 mmol). Purified using a gradient of 0-10% EtOAc/CH2Cl2. The title compound was obtained as a red solid (151 mg, 0.33 mmol, 77% yield). LCMS Method B (9.85 min); 1H NMR (400 MHz, DMSO-d6) 1H NMR (400 MHz, DMSO-d6) δ 10.88 (s, 1H), 10.71 (s, 1H), 8.74 (d, J=2.2 Hz, 1H), 8.14 (dd, J=3.8, 1.2 Hz, 1H), 8.11-8.00 (m, 5H), 7.93 (ddd, J=6.0, 4.9, 1.1 Hz, 2H), 7.90-7.82 (m, 2H), 7.28 (ddd, J=10.1, 5.0, 3.8 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 160.3, 159.8, 154.4, 143.9, 139.5, 139.2, 137.6, 137.3, 133.8, 132.8, 132.6, 130.0, 129.7, 128.5, 128.2, 123.1, 120.2, 118.5, 116.2, 113.4, 112.7; HRMS m/z calculated for C23H14N5O2S2[M−H]− 456.0589; found 456.0593; IR: 3286, 3100, 2223, 1646, 1580.
General procedure A was followed using 4-nitroaniline (500 mg, 3.62 mmol), NaNO2 (275 mg, 3.98 mmol), benzene-1,3-diamine (391 mg, 3.62 mmol) and NaOAc (891 mg, 10.9 mmol). Purified using a gradient of 20-80% EtOAc/CH2Cl2. The title compound was obtained as a black solid (289 mg, 1.12 mmol, 31% yield). LCMS Method A (1.03 min); 1H NMR (400 MHz, DMSO-d6) δ 8.23 (dd, J=9.2, 5.2 Hz, 2H), 7.81 (dd, J=9.0, 5.4 Hz, 2H), 7.40 (d, J=9.0 Hz, 1H), 6.44 (br. s, 2H), 6.10 (d, J=9.0 Hz, 1H), 5.87 (d, J=2.2 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 157.9, 155.2, 144.7, 130.8, 124.9, 121.0, 107.9, 95.3; HRMS m/z calculated for C12H12N5O2 [M+H]+ 258.0991; found 258.1000; IR: 3480, 3373, 3236, 1636, 1617.
General procedure B was followed using (E)-4-((4-nitrophenyl)diazenyl)benzene-1,3-diamine (161 mg, 0.63 mmol), furan-2-carboxylic acid (140 mg, 1.25 mmol) and T3P (1.1 mL, 1.9 mmol). Purified using a gradient of 0-20% EtOAc/CH2Cl2. The title compound was obtained as a red solid (203 mg, 0.46 mmol, 73% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.54 (s, 1H), 10.76 (s, 1H), 9.05 (d, J=2.3 Hz, 1H), 8.50 (d, J=9.1 Hz, 2H), 8.18-8.12 (m, 3H), 8.02-7.96 (m, 2H), 7.89 (dd, J=9.0, 2.2 Hz, 1H), 7.50 (dd, J=3.5, 0.8 Hz, 1H), 7.41 (dd, J=3.5, 0.8 Hz, 1H), 6.78 (ddd, J=20.2, 3.5, 1.7 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 156.5, 155.9, 155.3, 148.1, 147.2, 147.0, 146.6, 146.5, 144.4, 136.2, 136.0, 125.3, 124.4, 123.2, 115.9, 115.8, 112.8, 112.3, 111.3; HRMS m/z calculated for C22H14N5O6 [M−H]− 444.0944; found 444.0942; IR: 3412, 3357, 3114, 1684, 1581, 1506.
General procedure B was followed using (E)-4-((4-nitrophenyl)diazenyl)benzene-1,3-diamine (96 mg, 0.37 mmol), thiophene-2-carboxylic acid (95 mg, 0.74 mmol) and T3P (0.7 mL, 1.2 mmol). Purified using a gradient of 0-20% EtOAc/CH2Cl2. The title compound was obtained as a maroon solid (114 mg, 0.24 mmol, 64% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.91 (s, 1H), 10.73 (s, 1H), 8.77 (d, J=2.2 Hz, 1H), 8.45 (dd, J=9.0, 5.0 Hz, 2H), 8.18-8.09 (m, 3H), 8.04 (dd, J=3.8, 1.2 Hz, 1H), 7.98-7.82 (m, 4H), 7.29 (ddd, J=12.5, 4.9, 3.7 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 160.4, 159.9, 155.7, 148.1, 144.2, 139.5, 139.2, 137.8, 137.6, 132.9, 132.7, 130.1, 129.9, 128.6, 128.3, 125.2, 123.4, 120.2, 116.3, 113.4; HRMS m/z calculated for C22H14N5O4S2[M−H]− 476.0487; found 476.0485; IR: 3392, 3097, 1670, 1640, 1508.
Synthesised according to literature precedent1 from 3,5-dimethyl-4-nitro-1H-pyrazole. 1H NMR (400 MHz, CDCl3) δ 3.64 (s, 3H), 2.45 (br. s, 2H), 2.13 (s, 3H), 2.11 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 138.8, 128.1, 122.8, 36.1, 10.8, 8.9; HRMS m/z calculated for C6H12N3[M+H]+ 126.1026; found 126.1028.
General procedure A was followed using 1,3,5-trimethyl-1H-pyrazol-4-amine (1.56 g, 12.5 mmol), NaNO2 (947 mg, 13.7 mmol), benzene-1,3-diamine (1.35 g, 12.5 mmol) and NaOAc (3.07 g, 37.4 mmol). Purified using a gradient of 80-87% EtOAc/pentane (0.2% Et3N). The title compound was obtained as a reddish-brown solid (1.38 g, 5.66 mmol, 45% yield). LCMS Method A (1.17 min), 1H NMR (400 MHz, DMSO-d6) δ 7.27 (d, J=8.7 Hz, 1H), 6.23 (br. s, 2H), 5.93 (dd, J=8.5, 2.3 Hz, 1H), 5.89 (d, J=2.3 Hz, 1H), 5.51 (br. s, 2H), 3.68 (s, 3H), 2.43 (s, 3H), 2.28 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 151.5, 145.8, 138.9, 134.7, 134.2, 129.9, 125.0, 104.6, 97.9, 35.7, 13.7, 9.5; HRMS m/z calculated for C12H17N6 [M+H]+ 245.1515; found 245.1512; IR: 3421, 3430, 3314, 3379, 3198, 2918, 1617, 1497.
General procedure B was followed using (E)-4-((1,3,5-trimethyl-1H-pyrazol-4-yl)diazenyl)benzene-1,3-diamine (100 mg, 0.41 mmol), furan-2-carboxylic acid (91 mg, 0.82 mmol) and T3P (0.7 mL, 1.2 mmol). Purified using a gradient of 0-2% MeOH/CH2Cl2. The title compound was obtained as a yellow solid (109 mg, 0.25 mmol, 62% yield). LCMS Method C (15.49 min)1H NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H), 10.20 (s, 1H), 8.92 (d, J=2.1 Hz, 1H), 8.00-7.90 (m, 2H), 7.79-7.68 (m, 2H), 7.43 (dd, J=3.5, 0.9 Hz, 1H), 7.34 (d, J=3.5 Hz, 1H), 6.74 (ddd, J=11.6, 3.5, 1.7 Hz, 2H), 3.76 (s, 3H), 2.60 (s, 3H), 2.48 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 156.3, 155.2, 147.3, 146.1, 145.9, 140.7, 140.3, 140.1, 137.3, 135.3, 135.0, 116.0, 115.4, 115.1, 112.8, 112.2, 111.6, 69.8, 36.1, 14.2, 9.5; HRMS m/z calculated for C22H21N6O4 [M+H]+ 433.1621; found 433.1624; IR: 3421, 3340, 3307, 1680, 1647
General procedure B was followed using (E)-4-((1,3,5-trimethyl-1H-pyrazol-4-yl)diazenyl)benzene-1,3-diamine (110 mg, 0.45 mmol), thiophene-2-carboxylic acid (115 mg, 0.90 mmol) and T3P (0.8 mL, 1.4 mmol). Purified using a gradient of 0-2% MeOH/CH2Cl2. The title compound was obtained as a yellow solid (150 mg, 0.32 mmol, 71% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.52 (s, 1H), 10.16 (s, 1H), 8.52 (t, J=1.3 Hz, 1H), 8.11 (dd, J=3.8, 1.2 Hz, 1H), 7.97 (dd, J=3.7, 1.2 Hz, 1H), 7.90 (dt, J=5.1, 1.0 Hz, 2H), 7.75 (d, J=1.3 Hz, 2H), 7.25 (ddd, J=5.0, 3.8, 2.8 Hz, 2H), 3.74 (s, 3H), 2.55 (s, 3H), 2.35 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.0, 159.5, 140.5, 140.3, 139.8, 139.7, 139.7, 139.6, 135.4, 134.9, 132.3, 132.1, 129.5, 129.1, 128.3, 128.2, 116.8, 115.9, 114.7, 36.0, 14.0, 9.6; HRMS m/z calculated for C22H21N6O2S2 [M+H]+ 465.1160; found 465.1167; IR: 3358, 3248, 1653, 1597.
Crystallography data were obtained for TRPswitch-B: C22H20N6O2S2.CH4O, M=496.60, orthorhombic, P212121 (no. 19), a=6.3624(3), b=14.1164(8), c=27.4354(13) Å, V=2464.1(2) Å3, Z=4, Dc=1.339 g·cm−3, μ(Cu-Kα)=2.268 mm−1, T=173 K, yellow plates, Agilent Xcalibur PX Ultra A diffractometer; 4089 independent measured reflections (Rint=0.0588), F2 refinement [55, 56] R1(obs)=0.0534, wR2(all)=0.1334, 3286 independent observed absorption-corrected reflections [|Fo|>4σ(|Fo|), completeness to θfull (67.7°)=98.9%], 300 parameters. The absolute structure of TRPswitch-B was determined by use of the Flack parameter [x=0.01(3)]. CCDC 1962764.
The included solvent was found to be highly disordered, and the best approach to handling this diffuse electron density was found to be the SQUEEZE routine of PLATON [57]. This suggested a total of 90 electrons per unit cell, equivalent to 22.5 electrons per asymmetric unit. Before the use of SQUEEZE, the solvent most resembled methanol (CH4O, 18 electrons), and one methanol molecule corresponds to 18 electrons, so this was used as the solvent present. As a result, the atom list for the asymmetric unit is low by CH4O (and that for the unit cell low by C4H16O4) compared to what is actually presumed to be present.
The N—H hydrogen atoms on N17 and N24 were located from ΔF maps and refined freely subject to an N—H distance constraint of 0.90 Å. The structure is shown in
In order to determine the Z→E thermal isomerisation kinetics in DMSO-d6 a ˜20 mM solution of the relevant compound was irradiated using a Luzchem LZC-4V photoreactor fitted with 12×8 W LZC-420 lamps (420 nm peak emission) until no further change was observable by 1H NMR. For 30% water:DMSO samples, a 15 μM solution of the relevant compound was irradiated in a quartz cuvette using 365 nm LEDs (3×800 mW Nichia NCSU276A) until no further change was observed by UV-Vis spectroscopy. Compounds (˜25 μM solutions in DMSO) were treated analogously. In the case of compounds studied by NMR, the change in Z-isomer percentage was followed as a function of time through integration of the relevant peaks. In the case of compounds studied by UV-Vis, absorption spectra were collected over time while the sample was held at the stated temperature.
For data collected via 1H NMR, the natural log of the Z isomer concentration was plotted against time to yield a straight line implying first order kinetics. The gradient of this line was used to determine the rate constant for Z→E conversion from which the thermal half-life could be calculated:
For data collected via UV-Vis Spectroscopy, absorbance data at a fixed wavelength was fitted using the following, first order equation:
where k represents the rate constant; A∞, A0 and At are the absorbances of the pure E-state, Z-rich state, and time t, respectively. The gradient of this line was used to determine the rate constant for Z→E conversion from which the thermal half-life could be calculated, as per above.
Zebrafish (Danio rerio) wild-type TuAB or trpa1b mutant [35] larvae were used for all experiments. Zebrafish embryos were produced using group mating of adult zebrafish. Larvae were raised in E3 media 1×E3 media (0.68 mM NaCl, 0.18 mM KCl, 0.33 mM CaCl2, 0.4 mM MgCl2) and maintained in an incubator with a 14 h light/10 h dark cycle at 28.5° C. until experiments. The maintenance of adult animals, obtaining of embryos and larvae, and all experimental procedures were carried out according to protocols approved by the University of Utah's Institutional Animal Care and Use Committee (IACUC).
A total of 1,000 compounds were selected from the ChemBridge Corp. catalog. Compounds were dissolved in DMSO at a stock concentration of 1 μg/μL (˜1.5 mM). The library was screened at a 1:100 dilution in E3 solution for a final concentration of ˜15 μM. Negative controls were treated with an equal volume of DMSO. Groups of 3 larvae at 3 days post fertilization (dpf) were distributed into the wells of 96-well clear bottom black microplates (07-200-567; Fisher Scientific) in 150 μL E3 before the addition of small molecules. Stock solutions of compounds were added directly to zebrafish in the wells of a 96 well plate (Corning 3631), mixed, and allowed to incubate for 1 h in the dark at 28.5° C. prior to behavioral evaluation in the behavioral assay. Ordering information: 1 (5533696; ChemBridge); 3 (5538408; ChemBridge).
Larvae in each of the wells were exposed to four 1 second flashes of light stimulus in the following order: 450-500 nm (WL1), 415-455 nm (WL2), 352-402 nm (WL3), white light (WL4), with a 5 second inter-stimulus interval. Digital video recording was performed for 5 seconds before the first light stimuli and continued throughout the stimulation sequence. Band pass filters (Semrock FF02-475/50, FF02-435/40, FF01-377/50) were used to restrict the excitation light to the indicated wavelengths. Light-induced motion response was used as the assay readout as DMSO treated control larvae do not respond to light stimulus. 290 frames of digital video were recorded per well at 10 FPS using an EMCCD camera (C9100; Hamamatsu) mounted on an inverted compound microscope (AxioObserver A1; Zeiss) with a NA 0.03 1.25× objective and a barrier with a 0.7 mm diameter opening to restrict light scattering to the sample. MetaMorph software (Molecular Devices) was used to control the execution of TTL signals and camera capture using the built-in stream acquisition with trigger function. Each video was saved for review. Light stimuli were generated with an ozone free 300-Watt xenon bulb housed in a Lambda LS illuminator (Sutter Instruments). A dichroic mirror (T510LPXRXT; Chroma) was used for appropriate excitation of samples and bright field acquisition. Schott longpass absorption glass (RG610; Chroma) was added in the transmitted light path to reduce unwanted excitation to the well and to provide sufficient light for video recording. All behavioral experiments were conducted at room temperature.
For
For Trpa1b ohnolog and paralog rescue experiments, Trpa1b−/− embryos were injected with ngn1:zTrpa1b-2A-mCherry (partial plasmid sequence in SEQ ID NO:5), ngn1:zTrpa1a-2A-mCherry, ngn1:hTRPA1-2A-EGFP or ngn1:mTRPA1-2A-mCherry at the 1-cell stage for mosaic Rohon-beard neuron expression. Embryos were screened at 2 dpf for fluorescent expression in Rohon-beard neurons, incubated with 20 μM TRPswitch-B for 1 hr and decapitated posterior to the eyes right before experiments. NA 0.25 5× objective and 1 s WL3 light illumination was used.
To analyze digital video recordings, custom MetaMorph software scripts were used to automatically threshold the video to identify the area of larvae in each frame. Threshold images of the frames after each light activation event were overlaid to calculate a new combined threshold area. The motion index was calculated as the percentage change between the threshold area in the frame right before light activation and the new combined threshold area. This motion index correlates with the overall amount of motion in the well.
Immortalized HEK293T cells or human colonic fibroblast cells (CCD-18Co; ATCC) were used. HEK293T cells were plated on 12 mm2 cover slips and transiently transfected with 10 μg of Trpa1b plasmid (pCMV-zTrpa1b-FLAG) (SEQ ID NO:3) and 5 μg of mNeonGreen cDNA (Allele Biotechnology), then grown in a 6 cm plate for 24-48 h. CCD-18Co were cultured in Eagle's minimal essential medium with 10% FBS, 1× penicillin and streptomycin. CCD-18Co cells were plated on 12 mm cover slips and transiently transfected with 5 μg of zTrpa1b plasmid (pCMV-zTrpa1b-FLAG) together with 5 μg of mNeonGreen cDNA (Allele Biotechnology), then grown in a 10 cm3 plate for 48-72 h. After this time, the cover slips were transferred to a recording chamber containing an extracellular solution composed of 145 mM sodium gluconate, 4 mM KCl, 3 mM MgCl2, 10 mM D-glucose, 10 mM HEPES; pH 7.4 adjusted with NaOH. The internal solution contained 122 mM cesium methane sulfonate, 1.8 mM MgCl2, 9 mM EGTA, 14 mM creatine phosphate (sodium salt), 4 mM Mg-ATP, 0.3 mM Na-GTP, 10 mM HEPES, pH 7.2 adjusted with CsOH. Borosilicate glass pipettes with a resistance of 3-5 MO were used. Whole cell currents were measured on an Axopatch 200B amplifier (Molecular De-vices) under the control of pClamp software. Signals were digitized through a Digidata1550B interface (Molecular Devices). Currents were filtered at 5 kHz (lowpass, Bessel) and sampled at 10 kHz prior to analysis with Clampfit software (Molecular Devices). All the plots and statistical tests were performed on Excel (Microsoft corp.). Basal Trpa1b whole cell currents were measured with a ramp protocol (˜100 to +100 mV, at a holding potential of 0 mV). Photoactive compounds were perfused into the recording chamber and a fluorescent light generated by mercury vapor short arc (U-HGLGPS, OLYMPUS) filtered through an ET-ECFP 434/17 nm filter and through a ET-mCherry 560 nm filter (Chroma Technology) was switched “on” and “off” for 10 s. All experiments were performed at room temperature. The p values were calculated using a two-tailed, paired Student's t-test.
Heartbeat interruption experiments were performed in vivo on 2 dpf Tg(cm/c2:Trpa1b-2A-EGFP) [24] larvae in a Trpa1b−/− background. Larvae were pretreated with 20 μM of TRPswitch-A or TRPswitch-B in E3 at a final concentration of 1% DMSO for 1 h in the dark at 28.5° C. before experimental manipulation. Immediately prior to the onset of experiments, E3 solution was replaced with 0.2 mg/mL tricaine (Sigma, A5040) in E3 for anesthetizing the larvae. Violet light (352-402 nm) and green light (500-600 nm) were used for E to Z and Z to E isomerization, respectively. Violet and green light excitation were achieved using a band pass filter FF01-377/50 and an et500lp long pass barrier filter, respectively, together with a t600plxxr dichroic mirror and a 300-Watt xenon bulb light source (Sutter Instrument). Experiments were performed using a NA 0.6 40× air objective at room temperature. The zebrafish heart in the whole field of view was illuminated with 1 s violet light followed by various lengths of green light as indicated. Ventricle width measurement was performed using the ImageJ ‘measure’ function on the widest outer ventricle width every 100 ms.
Compounds were dissolved in DMSO at 250 μM and 260 μM for TRPswitch-A and TRPswitch-B, respectively and UV-Vis absorbance was measured using a NanoDrop 1000 (Thermo Scientific).
The PSS composition at 420 nm (LZC-420), 365 nm (3×800 mW Nichia NCSU276A LEDs) and 495 nm (3×750 mW Nichia NCSE119B-V1 LEDs), of the relevant compounds, was determined in both DMSO-d6 (via 1H NMR) and a 30% water:DMSO mixture using either 1H NMR or UV-Vis spectroscopy). In the latter case, the pure Z isomer spectrum was estimated using methods described in previous publications [32, 39, 41].
All results are expressed as means±SEM. Unless otherwise indicated, a two-tailed un-paired student's t test with Mann-Whitney post-test was used to determine p values. The criterion for statistical significance was p<0.05. Statistical analysis was performed using Prism (GraphPad Software).
With the discovery of photochromic soluble ligands (PCLs) as a means to control ion channel function using light [11-15] it was reasoned that molecular photoswitches for TRPA1 could be discovered using small molecule screening. To achieve this goal, a modified version of the behavioral assay was developed that was previously utilized to identify photoactivable, but non-photoreversible, ligands of TRPA1 [23]. This medium-throughput, semi-automated screening assay was performed using a 96-well plate format where three larvae per well were incubated with small molecules. A library of 1,000 structurally diverse small molecules enriched for molecular photoswitch moieties such as acylhydrazone [27] azobenzene [28-31], azoheteroaryl [32-33], and stilbene [31, 34] was screened. The particular focus was on molecular photoswitches that operate via a reversible E/Z isomerization using different wavelengths of light. In this assay, each well of a 96-well plate is illuminated with a series of different wavelengths of light (450-500 nm, 415-455 nm, 352-402 nm, and white light) for one second to induce isomerization of the photoswitchable compounds (
Wild-type 3-days-post-fertilization larvae (dpf) were used, as they have a relatively developed central nervous system and show no motion response to light exposure at this stage of development. Zebrafish larvae express Trpa1b in a subset of trigeminal and Rohon-Beard sensory neurons [35]. Activation of Trpa1b induces a reproducible and robust motion response [23-24, 35-36]. A light-induced motion response, due to the presence of a photoactivated ligand for ion channels such as Trpa1b, is used as the readout for the assay. DMSO treated larvae on each screening plate served as negative controls. Using this screening assay, TRPswitch-A, an azobenzene containing small molecule was identified with no previously annotated biological activity.
The presence of TRPswitch-A led to a light-induced motion response across multiple wavelengths, with the most activity in a bandwidth between 415-455 nm (WL2 in
The TRPswitch-A chemical structure contains an azobenzene and a 2-furamide group in both the ortho and para positions of one of the benzene rings (Table 1, Compound 1;
To further characterize the thermal half-lives of TRPswitches in conditions that more closely resemble those used in biological experiments, the thermal half-lives at higher water contents (30% water:DMSO solutions) were measured. The thermal half-lives of TRPswitch-A and -B were 43 min and 1 hour, respectively. When measurements were made in DMSO-d6, the half-lives for TRPswitch-A and -B were 11 and 17 hours, respectively. The thermal isomerization kinetics were also measured at 25° C. in 30% water:DMSO solutions (
To further characterize the photochemical properties of TRPswitches, the photostationary state (PSS) of TRPswitches in 30% water:DMSO solutions were examined via UV-Vis. By extrapolating a pure Z spectrum, using methodology outlined in previous publications [32, 39, 41], the PSS composition is approximated to be 86% Z at 365 nm and 73% E at 495 nm for TRPswitch-A; and 92% Z at 365 nm and 100% E at 495 nm for TRPswitch-B (
Optovin was previously identified as a photoactivable ligand for the Trpa1b channel and confirmed that its activity is abolished in Trpa1b mutant zebrafish. To determine if Trpa1b is necessary for TRPswitch's biological activity, a behavioral assay using Trpa1b mutant larvae was performed [35]. When Trpa1b mutant larvae were used, the TRPswitch light-induced motion response was abolished (
To characterize the stability and kinetics of Trpa1b/TRPswitch-dependent photocurrents, zebrafish Trpa1b activity was recorded in HEK293T cells. The light-induced activation and deactivation of Trpa1b/TRPswitch was triggered with violet and green light pulses, respectively (
To test the potential cross activity of TRPswitch-B on the zebrafish ohnolog Trpa1a and on mammalian orthologs, zebrafish Trpa1a, mouse TRPA1 or human TRPA1 were transiently re-expressed in the Rohon-beard neurons of mutant Trpa1b−/− zebrafish and performed light-induced motion response experiments in the presence of TRPswitch-B. Rescue experiments were performed in Trpa1b−/− zebrafish with transient mosaic re-expression of zebrafish Trpa1b (zTrpa1b), zebrafish Trpa1a (zTrpa1a), mouse TRPA1 (mTRPA1) or human TRPA1 (hTRAP1) in Rohon-beard neurons. Embryos were pre-treated with 20 μM TRPswitch-B and decapitated right before light stimulation to eliminate the light response mediated by the retina (Table 5). Percent response is the percentage of embryos that exhibited a light-induced motion response within 5 s after the 1 s WL3 illumination. Only the re-expression of zTrpa1b (SEQ ID NO:6) in Rohon-beard neurons in Trpa1b−/− embryos rescued the TRPswitch-B-mediated light-induced motion response. N is the number of embryos tested. Only re-expression of Trpa1b rescued the light-induced motion response of Trpa1b−/− mutants (Table 5). These results suggest that TRPswitch-B is specific to the zebrafish Trpa1b channel.
Most known activators of the TRPA1 channel are electrophilic ligands that covalently modify cysteines in TRPA1's cytoplasmic domain. Optovin, the previously identified photoactivable TRPA1 ligand, reacts with those cysteines through a photochemical reaction involving the generation of singlet oxygen species. DABCO, a singlet oxygen quencher and triplet energy acceptor can completely suppress the optovin response [23]. To determine whether or not TRPswitch is also photoactivated in a singlet oxygen-based mechanism, the ability of DABCO to suppress TRPswitch activity was tested and determined that it did not (
To demonstrate the practical utility of TRPswitch in vivo, a heartbeat interruption experiment was performed using a zebrafish transgenic line expressing Trpa1b in cardiomyocytes, Tg(cm/c2:Trpa1b-2A-EGFP), and by applying pulses of violet and green light to the zebrafish heart. Since proper calcium handling is important for normal heartbeat, heartbeat was used as the biological readout for the activation and deactivation of Trpa1b channels. During regular heartbeat cycles, an increase in intracellular calcium is required for cardiomyocyte contraction as calcium binding to troponin C leads to a conformational change that displaces tropomyosin from the actin binding sites. Calcium levels must then decrease for cardiomyocyte relaxation as calcium prevents tropomyosin from returning to its original conformation. It is hypothesized that a sustained elevation of intracellular calcium, such as with TRPA1 activation, will result in a sustained tetanic contraction of the heart and interrupt rhythmic beating.
In transgenic larvae treated with either TRPswitch-A or TRPswitch-B, the ventricle heartbeat could be stopped and would persist in a sustained systolic state after a brief 1 s illumination with violet light (
Photoswitchable control of Trpa1b activity by the TRPswitches was repeatable. Cyclical rounds of illumination using violet and green light induced the stopping and restarting of the ventricle heartbeat (
This application claims priority to U.S. Provisional Patent Application No. 62/885,102, filed on Aug. 9, 2019, which is incorporated by reference herein in its entirety.
This invention was made with United States government support under National Institutes of Health grant numbers R01DK082871 and K99NS112599. The United States government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2020/045317 | 8/7/2020 | WO |
Number | Date | Country | |
---|---|---|---|
62885102 | Aug 2019 | US |